{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:10:09Z","timestamp":1790755809344,"version":"4.1.0"},"reference-count":147,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020M681792"],"award-info":[{"award-number":["2020M681792"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872733"],"award-info":[{"award-number":["81872733"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872734"],"award-info":[{"award-number":["81872734"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173674"],"award-info":[{"award-number":["82173674"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejmech.2022.114142","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T11:22:56Z","timestamp":1642677776000},"page":"114142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond"],"prefix":"10.1016","volume":"231","author":[{"given":"Yue","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanglian","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhancheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9016-6201","authenticated-orcid":false,"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3827-0992","authenticated-orcid":false,"given":"Hai","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114142_bib1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41380-018-0133-2","article-title":"Protein misassembly and aggregation as potential convergence points for non-genetic causes of chronic mental illness","volume":"24","author":"Bradshaw","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejmech.2022.114142_bib2","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.chembiol.2021.04.011","article-title":"Targeted protein degradation: a promise for undruggable proteins","volume":"28","author":"Samarasinghe","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.ejmech.2022.114142_bib3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41586-018-0678-x","article-title":"Distinct proteostasis circuits cooperate in nuclear and cytoplasmic protein quality control","volume":"563","author":"Samant","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114142_bib4","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1083\/jcb.201612111","article-title":"Shaping proteostasis at the cellular, tissue, and organismal level","volume":"216","author":"Sala","year":"2017","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41580-020-0250-z","article-title":"Mechanisms, regulation and functions of the unfolded protein response","volume":"21","author":"Hetz","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1208\/s12248-018-0254-1","article-title":"Emerging cancer therapeutic targets in protein homeostasis","volume":"20","author":"Bastola","year":"2018","journal-title":"AAPS J."},{"key":"10.1016\/j.ejmech.2022.114142_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-biochem-060815-014616","article-title":"Mechanisms and functions of spatial protein quality control","volume":"86","author":"Sontag","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2022.114142_bib8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114142_bib9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the 'undruggable' cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114142_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-018-0775-7","article-title":"Safety and tolerability of antibody-drug conjugates in cancer","volume":"42","author":"Wolska-Washer","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejmech.2022.114142_bib11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114142_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semcancer.2018.04.001","article-title":"CRISPR\/Cas9 for cancer research and therapy","volume":"55","author":"Zhan","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib13","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1111\/febs.13110","article-title":"Genome modification by CRISPR\/Cas9","volume":"281","author":"Ma","year":"2014","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2022.114142_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1089\/nat.2017.0715","article-title":"Journey of siRNA: clinical developments and targeted delivery","volume":"28","author":"Nikam","year":"2018","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.ejmech.2022.114142_bib15","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA designs further improve in\u00a0vivo performance of GalNAc-siRNA conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2022.114142_bib16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/21691401.2017.1307210","article-title":"Advances in siRNA delivery in cancer therapy","volume":"46","author":"Singh","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"10.1016\/j.ejmech.2022.114142_bib17","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.aax3769","article-title":"Cellular quality control by the ubiquitin-proteasome system and autophagy","volume":"366","author":"Pohl","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114142_bib18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-019-0362-y","article-title":"Development of targeted protein degradation therapeutics","volume":"15","author":"Chamberlain","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib19","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/nchembio.1887","article-title":"Protein degradation: prime time for PROTACs","volume":"11","author":"Deshaies","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib20","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/acschembio.6b01068","article-title":"Proteolysis-targeting chimeras: induced protein degradation as a therapeutic strategy","volume":"12","author":"Ottis","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2022.114142_bib22","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.apsb.2020.11.009","article-title":"Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2022.114142_bib23","doi-asserted-by":"crossref","first-page":"113247","DOI":"10.1016\/j.ejmech.2021.113247","article-title":"Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy","volume":"216","author":"Ma","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib24","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1021\/acs.jmedchem.1c00895","article-title":"Molecular glues for targeted protein degradation: from serendipity to rational discovery","volume":"64","author":"Dong","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib25","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41594-021-00560-2","article-title":"Target-induced clustering activates Trim-Away of pathogens and proteins","volume":"28","author":"Zeng","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tips.2020.04.005","article-title":"Emerging new concepts of degrader technologies","volume":"41","author":"Ding","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2022.114142_bib27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114142_bib28","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41589-021-00851-1","article-title":"Bifunctional small molecules that mediate the degradation of extracellular proteins","volume":"17","author":"Caianiello","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cbf.3369","article-title":"The PROTAC technology in drug development","volume":"37","author":"Zou","year":"2019","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.ejmech.2022.114142_bib30","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.3390\/cancers13123079","article-title":"Targeting the ubiquitin-proteasome system for cancer therapeutics by small-molecule inhibitors","volume":"13","author":"LaPlante","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2022.114142_bib31","doi-asserted-by":"crossref","first-page":"105109","DOI":"10.1016\/j.bioorg.2021.105109","article-title":"PROTACs technology for targeting non-oncoproteins: advances and perspectives","volume":"114","author":"Wang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib32","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in\u00a0vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib33","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-molecule PROTACS: new approaches to protein degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2022.114142_bib34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4155\/fmc-2019-0340","article-title":"Small-molecule PROTACs: novel agents for cancer therapy","volume":"12","author":"Wan","year":"2020","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib35","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","article-title":"PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics","volume":"39","author":"Khan","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2022.114142_bib36","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A\u00a0selective BCL-X PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114142_bib37","unstructured":"U. S. National Library of Medicine. https:\/\/clinicaltrials.gov."},{"key":"10.1016\/j.ejmech.2022.114142_bib38","unstructured":"Center for Drug Evaluation, NMPA. http:\/\/www.chinadrugtrials.org.cn."},{"key":"10.1016\/j.ejmech.2022.114142_bib39","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1158\/1538-7445.AM2018-5236","article-title":"Abstract 5236: ARV-110: an androgen receptor PROTAC degrader for prostate cancer","volume":"78","author":"Neklesa","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114142_bib40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1538-7445.AM2021-44","article-title":"Abstract 44: the discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114142_bib41","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.drudis.2013.01.008","article-title":"Shifting from the single to the multitarget paradigm in drug discovery","volume":"18","author":"Medina-Franco","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2022.114142_bib42","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114142_bib43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nrd4201","article-title":"Targeting tumour-supportive cellular machineries in anticancer drug development","volume":"13","author":"Dobbelstein","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114142_bib44","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.drudis.2011.10.003","article-title":"Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects","volume":"16","author":"L\u00f6tsch","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2022.114142_bib45","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMp1101548","article-title":"Development of novel combination therapies","volume":"364","author":"Woodcock","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114142_bib46","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","article-title":"Rational design of multitarget-directed ligands: strategies and emerging paradigms","volume":"62","author":"Zhou","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib47","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1021\/acs.jmedchem.1c00649","article-title":"Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP","volume":"64","author":"Zheng","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib48","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41467-017-00954-1","article-title":"Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation","volume":"8","author":"Maniaci","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.114142_bib49","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1021\/acschembio.8b00693","article-title":"Homo-PROTACs for the chemical knockdown of cereblon","volume":"13","author":"Steinebach","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib50","doi-asserted-by":"crossref","DOI":"10.3791\/59472","article-title":"Chemical inactivation of the E3 ubiquitin ligase cereblon by pomalidomide-based homo-PROTACs","author":"Lindner","year":"2019","journal-title":"JoVE"},{"key":"10.1016\/j.ejmech.2022.114142_bib51","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.apsb.2020.11.022","article-title":"Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer","volume":"11","author":"He","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2022.114142_bib52","doi-asserted-by":"crossref","first-page":"7245","DOI":"10.1021\/acs.jmedchem.8b00664","article-title":"Small molecules simultaneously inhibiting p53-murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs): discovery of novel multitargeting antitumor agents","volume":"61","author":"He","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib53","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.1021\/acs.jmedchem.8b01749","article-title":"Allosteric modulator discovery: from serendipity to structure-based design","volume":"62","author":"Lu","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib54","doi-asserted-by":"crossref","first-page":"13764","DOI":"10.1002\/anie.201914525","article-title":"New promise and opportunities for allosteric kinase inhibitors","volume":"59","author":"Lu","year":"2020","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2022.114142_bib55","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1021\/acsmedchemlett.7b00247","article-title":"Targeting the allosteric site of oncoprotein BCR-ABL as an alternative strategy for effective target protein degradation","volume":"8","author":"Shimokawa","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114142_bib56","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1021\/acs.jmedchem.0c00471","article-title":"Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein","volume":"63","author":"Wang","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/acs.jmedchem.9b00810","article-title":"Design, synthesis, and biological evaluation of MEK PROTACs","volume":"63","author":"Vollmer","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib58","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","article-title":"Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation","volume":"79","author":"Burslem","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114142_bib59","doi-asserted-by":"crossref","first-page":"691093","DOI":"10.3389\/fchem.2021.691093","article-title":"Reversible covalent PROTACs: novel and efficient targeted degradation strategy","volume":"9","author":"Yuan","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib60","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.chembiol.2021.03.005","article-title":"The role of reversible and irreversible covalent chemistry in targeted protein degradation","volume":"28","author":"Kiely-Collins","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.ejmech.2022.114142_bib61","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2022.114142_bib62","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1039\/C9CC08238G","article-title":"Protein degradation through covalent inhibitor-based PROTACs","volume":"56","author":"Xue","year":"2020","journal-title":"Chem Commun (Camb)."},{"key":"10.1016\/j.ejmech.2022.114142_bib63","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/acschembio.8b01094","article-title":"PROTAC-mediated degradation of bruton's tyrosine kinase is inhibited by covalent binding","volume":"14","author":"Tinworth","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib64","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1038\/s41467-020-17997-6","article-title":"Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry","volume":"11","author":"Guo","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.114142_bib65","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbpa.2020.12.003","article-title":"The rise of covalent proteolysis targeting chimeras","volume":"62","author":"Gabizon","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib66","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/acschembio.8b01083","article-title":"Covalent ligand screening uncovers a RNF4 E3 ligase recruiter for targeted protein degradation applications","volume":"14","author":"Ward","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib67","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41589-019-0279-5","article-title":"Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16","volume":"15","author":"Zhang","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib68","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1021\/jacs.1c00990","article-title":"DCAF11 supports targeted protein degradation by electrophilic proteolysis-targeting chimeras","volume":"143","author":"Zhang","year":"2021","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114142_bib69","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41589-019-0304-8","article-title":"Harnessing the anti-cancer natural product nimbolide for targeted protein degradation","volume":"15","author":"Spradlin","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib70","doi-asserted-by":"crossref","first-page":"15543","DOI":"10.1038\/s41598-020-72491-9","article-title":"Bardoxolone conjugation enables targeted protein degradation of BRD4","volume":"10","author":"Tong","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2022.114142_bib71","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1021\/jacs.1c03980","article-title":"Discovery of a covalent FEM1B recruiter for targeted protein degradation applications","volume":"144","author":"Henning","year":"2022","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114142_bib72","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/acschembio.6b01068","article-title":"Proteolysis-targeting chimeras: induced protein degradation as a therapeutic strategy","volume":"12","author":"Ottis","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib73","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.ejmech.2022.114142_bib74","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","article-title":"Acquired resistance to BET-PROTACs (Proteolysis-Targeting chimeras) caused by genomic alterations in core components of E3 ligase complexes","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114142_bib75","doi-asserted-by":"crossref","first-page":"678077","DOI":"10.3389\/fcell.2021.678077","article-title":"Light-controllable PROTACs for temporospatial control of protein degradation","volume":"9","author":"Liu","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib76","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/jacs.9b06422","article-title":"Light-induced protein degradation with photocaged PROTACs","volume":"141","author":"Xue","year":"2019","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114142_bib77","article-title":"Light-induced control of protein destruction by opto-PROTAC","volume":"6","author":"Liu","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2022.114142_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay5064","article-title":"PHOTACs enable optical control of protein degradation","volume":"6","author":"Reynders","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2022.114142_bib79","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1021\/acs.jmedchem.9b02058","article-title":"Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown","volume":"63","author":"Jin","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib80","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/acscentsci.9b00713","article-title":"Reversible spatiotemporal control of induced protein degradation by bistable PhotoPROTACs","volume":"5","author":"Pfaff","year":"2019","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2022.114142_bib81","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1021\/acs.jmedchem.0c01845","article-title":"Antibody-mediated delivery of chimeric BRD4 degraders. Part 1: exploration of antibody linker, payload loading, and payload molecular properties","volume":"64","author":"Dragovich","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib82","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1021\/acs.jmedchem.0c01846","article-title":"Antibody-mediated delivery of chimeric BRD4 degraders. Part 2: improvement of in\u00a0vitro antiproliferation activity and in\u00a0vivo antitumor efficacy","volume":"64","author":"Dragovich","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib83","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib84","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.tibtech.2014.03.001","article-title":"Nanobody-based products as research and diagnostic tools","volume":"32","author":"De Meyer","year":"2014","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ejmech.2022.114142_bib85","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.molcel.2020.04.032","article-title":"Antibody RING-mediated destruction of endogenous proteins","volume":"79","author":"Ibrahim","year":"2020","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114142_bib86","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1080\/10717544.2021.1943055","article-title":"Development of a human antibody fragment directed against the alpha folate receptor as a promising molecule for targeted application","volume":"28","author":"Parakasikron","year":"2021","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejmech.2022.114142_bib87","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1021\/jacs.1c00451","article-title":"Cancer selective target degradation by folate-caged PROTACs","volume":"143","author":"Liu","year":"2021","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114142_bib88","doi-asserted-by":"crossref","first-page":"12273","DOI":"10.1021\/acs.jmedchem.1c00901","article-title":"Folate-guided protein degradation by immunomodulatory imide drug-based molecular glues and proteolysis targeting chimeras","volume":"64","author":"Chen","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib89","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2018.08.005","article-title":"Aptamer-based targeted therapy","volume":"134","author":"Zhu","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2022.114142_bib90","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ijbiomac.2019.11.118","article-title":"Therapeutic applications of AS1411 aptamer, an update review","volume":"155","author":"Yazdian-Robati","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2022.114142_bib91","doi-asserted-by":"crossref","first-page":"23299","DOI":"10.1002\/anie.202107347","article-title":"Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer","volume":"60","author":"He","year":"2021","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2022.114142_bib92","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/s41467-021-23194-w","article-title":"Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.114142_bib93","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1021\/acs.jmedchem.8b01668","article-title":"Inhibitor of apoptosis protein (IAP) antagonists in anticancer agent discovery: current status and perspectives","volume":"62","author":"Cong","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib94","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fchem.2019.00849","article-title":"Targeted protein degradation by chimeric small molecules, PROTACs and SNIPERs","volume":"7","author":"Naito","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib95","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1021\/ja100691p","article-title":"Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins","volume":"132","author":"Itoh","year":"2010","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114142_bib96","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1016\/j.bmc.2011.03.057","article-title":"Development of target protein-selective degradation inducer for protein knockdown","volume":"19","author":"Itoh","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib97","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1016\/j.bmcl.2012.04.134","article-title":"Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist","volume":"22","author":"Itoh","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114142_bib98","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/mol.116.105569","article-title":"Targeted degradation of proteins localized in subcellular compartments by hybrid small molecules","volume":"91","author":"Okuhira","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114142_bib99","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","article-title":"The rise of molecular glues","volume":"184","author":"Schreiber","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114142_bib100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114142_bib101","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114142_bib102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41589-019-0411-6","article-title":"Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex","volume":"16","author":"Bussiere","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib103","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf6532","article-title":"RETINOBLASTOMA RELATED1 mediates germline entry in Arabidopsis","volume":"356","author":"Zhao","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114142_bib104","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nchembio.2363","article-title":"Selective degradation of splicing factor CAPER\u03b1 by anticancer sulfonamides","volume":"13","author":"Uehara","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib105","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-020-2374-x","article-title":"The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K","volume":"585","author":"S\u0142abicki","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114142_bib106","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood.2020008676","article-title":"CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells","volume":"137","author":"Surka","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114142_bib107","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib108","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.jmedchem.0c01489","article-title":"CC-90009: a cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia","volume":"64","author":"Hansen","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib109","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","article-title":"Targeted protein degraders crowd into the clinic","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114142_bib110","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/487308a","article-title":"Chemical biology: greasy tags for protein removal","volume":"487","author":"Neklesa","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114142_bib111","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1021\/cb400569k","article-title":"A\u00a0bidirectional system for the dynamic small molecule control of intracellular fusion proteins","volume":"8","author":"Neklesa","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib112","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/cbic.201100793","article-title":"Identification of hydrophobic tags for the degradation of stabilized proteins","volume":"13","author":"Tae","year":"2012","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2022.114142_bib113","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nchembio.597","article-title":"Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins","volume":"7","author":"Neklesa","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib114","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/nchembio.1658","article-title":"Pharmacological targeting of the pseudokinase Her3","volume":"10","author":"Xie","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib115","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1002\/anie.201503720","article-title":"Small-molecule-mediated degradation of the androgen receptor through hydrophobic tagging","volume":"54","author":"Gustafson","year":"2015","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2022.114142_bib116","doi-asserted-by":"crossref","first-page":"40362","DOI":"10.1039\/C7RA05347A","article-title":"Hydrophobic tagging-mediated degradation of Alzheimer's disease related Tau","volume":"7","author":"Gao","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2022.114142_bib117","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.chembiol.2012.04.008","article-title":"Inhibitor mediated protein degradation","volume":"19","author":"Long","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib118","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chembiol.2017.05.024","article-title":"Targeted protein degradation: from chemical biology to drug discovery","volume":"24","author":"Cromm","year":"2017","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.ejmech.2022.114142_bib119","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","article-title":"The dTAG system for immediate and target-specific protein degradation","volume":"14","author":"Nabet","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib120","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nature21688","article-title":"Transcription control by the ENL YEATS domain in acute leukaemia","volume":"543","author":"Erb","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114142_bib121","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1038\/s41467-020-18377-w","article-title":"Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules","volume":"11","author":"Nabet","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.114142_bib122","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.cell.2017.10.033","article-title":"A\u00a0method for the acute and rapid degradation of endogenous proteins","volume":"171","author":"Clift","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114142_bib123","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1038\/s41596-018-0028-3","article-title":"Acute and rapid degradation of endogenous proteins by Trim-Away","volume":"13","author":"Clift","year":"2018","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2022.114142_bib124","doi-asserted-by":"crossref","first-page":"2010556","DOI":"10.1002\/adfm.202010556","article-title":"Nanogel-facilitated protein intracellular specific degradation through trim-away","volume":"31","author":"Sui","year":"2021","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.ejmech.2022.114142_bib125","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1158\/2159-8290.CD-RW2020-119","article-title":"LYTACs target extracellular and membrane proteins for degradation","volume":"10","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2022.114142_bib126","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3390\/vaccines9070724","article-title":"Bispecific antibodies: a smart arsenal for cancer immunotherapies","volume":"9","author":"You","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ejmech.2022.114142_bib127","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114142_bib128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cell.2018.09.048","article-title":"Biological functions of autophagy genes: a disease perspective","volume":"176","author":"Levine","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114142_bib129","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1042\/EBC20170035","article-title":"Regulation of selective autophagy: the p62\/SQSTM1 paradigm","volume":"61","author":"Lamark","year":"2017","journal-title":"Essays Biochem."},{"key":"10.1016\/j.ejmech.2022.114142_bib130","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: cargo-specific degraders using selective autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114142_bib131","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114142_bib132","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/15548627.2019.1688556","article-title":"ATTEC: a potential new approach to target proteinopathies","volume":"16","author":"Li","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.ejmech.2022.114142_bib133","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1080\/15548627.2021.1967616","article-title":"Targeting lipid droplets for autophagic degradation by ATTEC","volume":"17","author":"Fu","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.ejmech.2022.114142_bib134","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2018.05.010","article-title":"Chaperone-mediated autophagy: advances from bench to bedside","volume":"122","author":"Li","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2022.114142_bib135","doi-asserted-by":"crossref","first-page":"101025","DOI":"10.1016\/j.mam.2021.101025","article-title":"Chaperone-mediated autophagy and disease: implications for cancer and neurodegeneration","volume":"82","author":"G\u00f3mez-Sintes","year":"2021","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.ejmech.2022.114142_bib136","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nn.3637","article-title":"Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation","volume":"17","author":"Fan","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114142_bib137","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41589-018-0161-x","article-title":"HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity","volume":"15","author":"Wang","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib138","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.14336\/AD.2018.1225","article-title":"The peptide-directed lysosomal degradation of CDK5 exerts therapeutic effects against stroke","volume":"10","author":"Zhou","year":"2019","journal-title":"Aging Dis"},{"key":"10.1016\/j.ejmech.2022.114142_bib139","doi-asserted-by":"crossref","first-page":"15448","DOI":"10.1002\/anie.202004310","article-title":"Prey for the proteasome: targeted protein degradation-A medicinal chemist's perspective","volume":"59","author":"Luh","year":"2020","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2022.114142_bib140","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41589-020-0596-8","article-title":"Chemical strategies to overcome resistance against targeted anticancer therapeutics","volume":"16","author":"Pisa","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114142_bib141","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2022.114142_bib142","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-019-0440-x","article-title":"Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas","volume":"33","author":"Sun","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2022.114142_bib143","doi-asserted-by":"crossref","first-page":"8902","DOI":"10.1021\/jacs.1c03852","article-title":"TF-PROTACs enable targeted degradation of transcription factors","volume":"143","author":"Liu","year":"2021","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114142_bib144","doi-asserted-by":"crossref","first-page":"13044","DOI":"10.1021\/jacs.1c02248","article-title":"Reprogramming of protein-targeted small-molecule medicines to RNA by ribonuclease recruitment","volume":"143","author":"Zhang","year":"2021","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114142_bib145","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1021\/acs.jmedchem.0c02054","article-title":"Optimization of CAR-T cell-based therapies using small-molecule-based safety switches","volume":"64","author":"Zheng","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114142_bib146","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.drudis.2020.08.007","article-title":"Could PROTACs protect us from COVID-19?","volume":"25","author":"Martinez-Ortiz","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2022.114142_bib147","doi-asserted-by":"crossref","first-page":"113814","DOI":"10.1016\/j.ejmech.2021.113814","article-title":"Indomethacin-based PROTACs as pan-coronavirus antiviral agents","volume":"226","author":"Desantis","year":"2021","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422000447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422000447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:35:11Z","timestamp":1759329311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422000447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":147,"alternative-id":["S0223523422000447"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114142","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114142"}}